536 RANIDO trial: Racotumomab-alum vaccine, Nimotuzumab or Docetaxel as switch maintenance therapy for advanced NSCLC. (September 2015) - Hernandez, M.; Neninger, E.; Santiesteban, E.; Ortiz, R.; Amador, R.; Bello, L.; Acosta, S.; Flores, Y.; Cala, M.; Martínez, O.; Calana, A.; Pichs, G.; et al.